2006, Volume 13, Supplement 2: The role of angiotensin-converting enzyme inhibitors in coronary artery disease

Perindopril has recently been granted a licence extension for the treatment of stable coronary artery disease, to reduce the risk of cardiac events in patients with a history of myocardial infarction (MI) and/or revascularisation. Dr Kristian Bailey and Professor Alistair Hall review the evidence behind this extended role for angiotensin-converting enzyme (ACE) inhibitors and discuss whether this role applies across the whole class....